Evidence map›Paper›PMID 37782657›Full record

ArticlePLoS pathogens2023

Proximity-dependent mapping of the HCMV US28 interactome identifies RhoGEF signaling as a requirement for efficient viral reactivation.

Samuel Medica, Lindsey B Crawford, Michael Denton, Chan-Ki Min, Taylor A Jones, Timothy Alexander, Christopher J Parkins, Nicole L Diggins, Gabriel J Streblow, Adam T Mayo and 9 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Human cytomegalovirus and neonatal infection.Current research in microbial sciences · 2024
    Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Samuel MedicaVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
Lindsey B CrawfordVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
Michael DentonVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
Chan-Ki MinDepartment of Microbiology & Immunology, Center for Molecular & Tumor Virology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana, United States of America.
Taylor A JonesVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
Timothy AlexanderVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
Christopher J ParkinsVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
Nicole L DigginsVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
Gabriel J StreblowVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
Adam T MayoVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
Craig N KreklywichVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
Patricia SmithVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
Sophia JengDepartment of Bioinformatics and Computational Biology, Oregon Health and Science University, Portland, Oregon, United States of America.
Shannon McWeeneyDepartment of Bioinformatics and Computational Biology, Oregon Health and Science University, Portland, Oregon, United States of America.
Meaghan H HancockVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
Andrew YurochkoDepartment of Microbiology & Immunology, Center for Molecular & Tumor Virology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana, United States of America.
Michael S CohenDepartment of Chemical Physiology and Biochemistry, Oregon Health and Science University, Portland, Oregon, United States of America.
Patrizia CaposioVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.
Daniel N StreblowVaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, Oregon, United States of America.ORCID 0000-0002-6828-2492
Oregon Health & Science University · USLouisiana State University Health Sciences Center Shreveport · USOregon National Primate Research Center · US

Funding

The Administrative CoreP01AI127335 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI Patrizia Caposio · 2017 to 2026
$24.6M
Project 4-Tracking cytomegalovirus-primed long-lived NK cells in salivary glandP20GM134974 · NIGMS · LOUISIANA STATE UNIV HSC SHREVEPORT · PI ANDREW D YUROCHKO · 2021 to 2026
$15.0M
NIAID NIH HHS P01 AI127335NIGMS NIH HHS P20 GM134974
6 · The paper itself

Abstract

Human cytomegalovirus (HCMV) encodes multiple putative G protein-coupled receptors (GPCRs). US28 functions as a viral chemokine receptor and is expressed during both latent and lytic phases of virus infection. US28 actively promotes cellular migration, transformation, and plays a major role in mediating viral latency and reactivation; however, knowledge about the interaction partners involved in these processes is still incomplete. Herein, we utilized a proximity-dependent biotinylating enzyme (TurboID) to characterize the US28 interactome when expressed in isolation, and during both latent (CD34+ hematopoietic progenitor cells) and lytic (fibroblasts) HCMV infection. Our analyses indicate that the US28 signalosome converges with RhoA and EGFR signal transduction pathways, sharing multiple mediators that are major actors in processes such as cellular proliferation and differentiation. Integral members of the US28 signaling complex were validated in functional assays by immunoblot and small-molecule inhibitors. Importantly, we identified RhoGEFs as key US28 signaling intermediaries. In vitro latency and reactivation assays utilizing primary CD34+ hematopoietic progenitor cells (HPCs) treated with the small-molecule inhibitors Rhosin or Y16 indicated that US28 -RhoGEF interactions are required for efficient viral reactivation. These findings were recapitulated in vivo using a humanized mouse model where inhibition of RhoGEFs resulted in a failure of the virus to reactivate. Together, our data identifies multiple new proteins in the US28 interactome that play major roles in viral latency and reactivation, highlights the utility of proximity-sensor labeling to characterize protein interactomes, and provides insight into targets for the development of novel anti-HCMV therapeutics.

Indexed as

CytomegalovirusSignal TransductionAnimalsCell DifferentiationHematopoietic Stem CellsHumansMiceVirus Latency

Identifiers

PMID37782657
PMCPMC10569644
OpenAlexW4387251873

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.